利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.026 秒)

    NOVEL ADENINE COMPOUND
    1.
    发明公开
    NOVEL ADENINE COMPOUND 审中-公开
    新的腺嘌呤化合物

    公开(公告)号：EP1939202A1

    公开(公告)日：2008-07-02

    申请号：EP06810299.5

    申请日：2006-09-20

    申请人： Dainippon Sumitomo Pharma Co., Ltd. ,  AstraZeneca AB

    发明人： HASHIMOTO, Kazuki ,  NAKAMURA, Tomoaki ,  NAKAMURA, Kei ,  KURIMOTO, Ayumu ,  ISOBE, Yoshiaki

    IPC分类号： C07D473/18 ,  A61K31/522 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/5513 ,  A61P11/02 ,  A61P11/06 ,  A61P17/00 ,  A61P27/02 ,  A61P31/12 ,  A61P31/18 ,  A61P35/00 ,  A61P37/02 ,  A61P37/08 ,  A61P43/00 ,  C07D473/16 ,  C07D473/24 ,  C07D473/34 ,  C07D519/00

    CPC分类号： C07D473/16 ,  C07D473/18 ,  C07D519/00

    摘要： An adenine compound useful for a medicament represented by the following formula (1):

    , wherein A 1 and A 2 are independently, optionally substituted cyclic aromatic hydrocarbon group or optionally substituted aromatic heterocyclic group;
    L 1 , L 2 and L 3 are independently, alkylene or a single optionally substituted alkylene or a single bond, and any methylene or methyne in L 2 or L 3 may be bound with N atom adjacent to L 2 and L 3 to form 4 to 7 membered saturated hetero ring containing N atom;
    L 4 is alkylene or a single bond;
    R 1 is optionally substituted alkyl group, optionally substituted alkenyl group, optionally substituted aryl group, etc.;
    R 2 is hydrogen atom or optionally substituted alkyl group;
    R 3 is optionally substituted alkyl group, etc.;
    X is oxygen atom, etc.;
    or its pharmaceutically acceptable salt.

    摘要翻译： 一种用于由下式（1）表示的药物的腺嘌呤化合物：其中A1和A2独立地为任选取代的环状芳族烃基或任选取代的芳族杂环基; L 1，L 2和L 3独立地为亚烷基或单个任选取代的亚烷基或单键，并且L 2或L 3中的任何亚甲基或亚甲基可以与与L 2和L 3相邻的N原子结合以形成4至7元饱和杂环， N原子; L 4是亚烷基或单键; R 1是任选取代的烷基，任选取代的烯基，任选取代的芳基等; R2是氢原子或任选取代的烷基; R3是任选取代的烷基等; X是氧原子等; 或其药学上可接受的盐。

    NOVEL ADENINE COMPOUND
    3.
    发明公开
    NOVEL ADENINE COMPOUND 审中-公开
    新的腺嘌呤化合物

    公开(公告)号：EP1939199A1

    公开(公告)日：2008-07-02

    申请号：EP06798200.9

    申请日：2006-09-21

    申请人： Dainippon Sumitomo Pharma Co., Ltd. ,  AstraZeneca AB

    发明人： HASHIMOTO, Kazuki ,  NAKAMURA, Tomoaki ,  NAKAMURA, Kei ,  TOJO, Shingo ,  KURIMOTO, Ayumu ,  ISOBE, Yoshiaki ,  WADA, Hiroki ,  BONNERT, Roger

    IPC分类号： C07D473/18 ,  A61K31/522 ,  A61P11/02 ,  A61P11/06 ,  A61P17/00 ,  A61P27/02 ,  A61P31/12 ,  A61P31/18 ,  A61P35/00 ,  A61P37/02 ,  A61P37/08 ,  A61P43/00

    CPC分类号： C07D473/18

    摘要： An adenine compound useful as a medicine represented by the following formula (1):

    [wherein R 1 is halogen atom, optionally substituted alkyl group, optionally substituted aryl group, etc.;
    X is oxygen atom, sulfur atom, a single bond, etc.;
    A 1 is optionally substituted and optionally saturated 4 to 8 membered
    heterocyclic group containing 1 to 2 hetero atoms selected from 1 to 3 nitrogen atoms, 0 to 1 oxygen atom, and 0 to 1 sulfur atom;
    A 2 is optionally substituted 6 to 10 cyclic aromatic hydrocarbon group or optionally substituted 5 to 10 membered heterocyclic aromatic group;
    L 1 and L 2 are independently, substituted straight or branched alkylene or a single bond, etc.;
    L 3 is optionally substituted straight or branched alkylene, etc.;
    R 2 is hydrogen atom, optionally substituted alkyl group.]
    or its pharmaceutically acceptable salt.

    摘要翻译： 一种腺嘌呤化合物，用作由下式（1）表示的药物：[其中R1是卤素原子，任选取代的烷基，任选取代的芳基等; X是氧原子，硫原子，单键等; A1是含有1至2个选自1至3个氮原子，0至1个氧原子和0至1个硫原子的杂原子的任选取代的和任选饱和的4至8元杂环基团; A2任选被取代的6至10个环状芳族烃基或任选取代的5至10元杂环芳基; L 1和L 2独立地为取代的直链或支链亚烷基或单键等; L3是任选取代的直链或支链亚烷基等; R2是氢原子，任选取代的烷基。]或其药学上可接受的盐。

    NOVEL ADENINE COMPOUND
    5.
    发明公开
    NOVEL ADENINE COMPOUND 审中-公开
    新的腺嘌呤化合物

    公开(公告)号：EP2133353A1

    公开(公告)日：2009-12-16

    申请号：EP08738671.0

    申请日：2008-03-19

    申请人： Dainippon Sumitomo Pharma Co., Ltd. ,  AstraZeneca AB

    发明人： ISOBE, Yoshiaki ,  NAKAMURA, Tomoaki

    IPC分类号： C07D473/00 ,  A61K31/522 ,  A61K31/5377 ,  A61K31/551 ,  A61P1/04 ,  A61P3/10 ,  A61P9/00 ,  A61P9/12 ,  A61P11/00 ,  A61P11/02 ,  A61P11/06 ,  A61P11/14 ,  A61P13/02 ,  A61P13/08 ,  A61P13/12 ,  A61P15/00 ,  A61P15/10 ,  A61P17/00 ,  A61P17/06 ,  A61P17/14

    CPC分类号： C07D473/24 ,  C07D473/00 ,  C07D473/16 ,  C07D473/18 ,  C07D473/34

    摘要： A novel adenine compound represented by the formula (1):

    wherein A represents an (un)substituted aromatic carbocycle or (un)substituted aromatic heterocycle; L 1 and L 2 each independently represents straighted or branched alkylene, etc.; R 1 represents halogen, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted cycloalkyl, (un)substituted aryl, or (un)substituted heteroaryl; R 2 and R 3 each independently represents hydrogen, or (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted cycloalkyl, (un)substituted saturated heterocycle, (un)substituted aryl, or (un)substituted heteroaryl, or R 2 combines together with L 2 or R 3 to form (un)substituted 4- to 8-membered nitrogen-containing saturated heterocycle; X is oxygen, sulfur, SO, SO 2 , NR 7 , NR 7 CO wherein R 7 is hydrogen or alkyl, or a single bond; provided that X is a single bond when R 1 is halogen, or a pharmaceutically acceptable salt thereof. The compound and salt are useful as a medicine.

    摘要翻译： 由式（1）表示的新型腺嘌呤化合物：其中A表示（未）取代的芳族碳环或（未）取代的芳族杂环; L1和L2各自独立地表示直链或支链亚烷基等; （未）取代的烷基，（未）取代的烯基，（未）取代的炔基，（未）取代的环烷基，（未）取代的芳基或（未）取代的杂芳基; （未）取代的烯基，（未）取代的炔基，（未）取代的环烷基，（未）取代的饱和杂环，（未）取代的芳基或（未）取代的芳基。 取代的杂芳基，或R2与L2或R3一起形成（未）取代的4-至8-元含氮饱和杂环; X是氧，硫，SO，SO 2，NR 7，NR 7 CO，其中R 7是氢或烷基或单键; 条件是当R1是卤素时X是单键，或其药学上可接受的盐。 该化合物和盐可用作药物。

    NOVEL ADENINE COMPOUND
    6.
    发明公开
    NOVEL ADENINE COMPOUND 审中-公开
    新的腺嘌呤化合物

    公开(公告)号：EP1939201A1

    公开(公告)日：2008-07-02

    申请号：EP06798243.9

    申请日：2006-09-22

    申请人： Dainippon Sumitomo Pharma Co., Ltd. ,  AstraZeneca AB

    发明人： ISOBE, Yoshiaki ,  KURIMOTO, Ayumu ,  HASHIMOTO, Kazuki ,  NAKAMURA, Tomoaki ,  NAKAMURA, Kei

    IPC分类号： C07D473/18 ,  A61K31/522 ,  A61P11/02 ,  A61P11/06 ,  A61P17/00 ,  A61P27/02 ,  A61P31/12 ,  A61P31/18 ,  A61P35/00 ,  A61P37/02 ,  A61P37/08 ,  A61P43/00 ,  C07D473/16 ,  C07D473/24 ,  C07D473/34

    CPC分类号： C07D473/18

    摘要： A novel adenine compound represented by the formula (1):

    wherein A represents an (un)substituted aromatic carbocycle or (un)substituted aromatic heterocycle; L 1 , L 2 , and L 3 each independently represents linear or branched alkylene, etc.; R 1 represents (un)substituted alkyl, (un)substituted aryl, etc.; R 2 represents hydrogen or (un)substituted alkyl; R 3 represents (un)substituted alkyl, etc., provided that R 3 may be bonded to L 2 or L 3 to form a nitrogenous saturated heterocycle; and X represents oxygen, etc.; or a pharmaceutically acceptable salt of the compound. The compound and salt are useful as a medicine.

    摘要翻译： 由式（1）表示的新型腺嘌呤化合物：其中A表示（未）取代的芳族碳环或（未）取代的芳族杂环; L1，L2和L3各自独立地表示直链或支链亚烷基等; （未）取代的烷基，（未）取代的芳基等。 R2代表氢或（未）取代的烷基; R3代表（未）取代的烷基等，条件是R3可以与L2或L3结合形成含氮饱和杂环; X代表氧等; 或该化合物的药学上可接受的盐。 该化合物和盐可用作药物。